Info

Rosenbaum SE, Lam J. Bioequivalence parameters of parent drug and its first-pass metabolite: comparative sensitivity to sources of pharmacokinetic variability. Drug Dev Ind Pharm 1997; 23:337-344.

Rosenbaum SE. Effect of variability in hepatic clearance on the bioequivalence parameters of a drug and its metabolite: simulations using a pharmacostatistical model. Pharm Acta Helv 1998; 73:135-144.

Jackson AJ. The role of metabolites in bioequivalency assessment. IE: Highly variable drugs with linear kinetics and first-pass effect. Pharm Res 2000; 17:1432-1436. Midha KK, Rawson MJ, Hubbard JW. The role of metabolites in bioequivalence. Pharm Res 2004; 21:1331-1344.

Amidon GL, Lennernaes H, Shah VP, et al. A theoretical basis for a biopharmaceutic drug classification: the correlation of in vitro drug product dissolution and in vivo bioavailability. Pharm Res 1995; 12(3):413^120.

European Medicines Evaluation Agency, Committee for Medicinal Products for Human use (CHMP), Concept paper on BCS-based biowaiver. Doc. Ref. EMEA/CHMP/EWP/213035/ 2007, London May 24, 2007.

Bonlokke L, Hovgaard L, Kristensen HG, et al. Direct estimation of the in vivo dissolution of spironolactone, in two particle size ranges, using the single-pass perfusion technique (Loc-I-Gut) in humans. Eur J Pharm Sei 2001; 12(3):239-250.

Weitschies W, Wedemeyer RS, Kosch O, et al. Impact of the intragastric location of extended release tablets on food interactions. J Control Release 2005; 108(2-3):375-385. Galia E, Nicolaides E, Hörter D, et al. Evaluation of various dissolution media for predicting in vivo performance of class I and II drugs. Pharm Res 1998; 15(5):698-705.

89. Persson EM, Gustafsson AS, Carlsson AS, et al. The effects of food on the dissolution of poorly soluble drugs in human and in model small intestinal fluids. Pharm Res 2005; 22(12): 2141-2151.

90. Kalantzi L, Persson E, Polentarutti B, et al. Canine intestinal contents vs. simulated media for the assessment of solubility of two weak bases in the human small intestinal contents. Pharm Res 2006; 23(6): 1373-1381.

91. Clarysse S, Psachoulias D, Brouwers J, et al. Postprandial Changes in solubilizing capacity of human intestinal fluids for BCS Class II Drugs. Pharm Res 2009, in press.

92. Pedersen BL, Mullertz A, Brondsted H, et al. A comparison of the solubility of danazol in human and simulated gastrointestinal fluids. Pharm Res 2000; 17(7):891-894.

93. Dressman JB, Vertzoni M, Goumas K, et al. Estimating drug solubility in the gastrointestinal tract. Adv Drug Deliv Rev 2007; 59(7):591-602.

94. Winiwarter S, Bonham NM, Ax F, et al. Correlation of human jejunal permeability (in vivo) of drugs with experimentally and theoretically derived parameters. A multivariate data analysis approach. J Med Chem 1998; 41(25):4939^1949.

95. Benet L, Amidon GL, Barends D, et al. The use of BDDCS in classifying the permeability of marketed drugs. Pharm Res 2008; 25(3):483^188 [Epub January 31, 2008].

96. Takagi T, Ramachandran C, Bermejo M, et al. A provisional biopharmaceutical classification of the top 200 oral drug products in the United States, Great Britain, Spain, and Japan. Mol Pharm 2006; 3(6):631-643.

97. Kasim NA, Whitehouse M, Ramachandran C, et al. Molecular properties of WHO essential drugs and provisional biopharmaceutical classification. Mol Pharm 2004; l(l):85-96.

98. Lindenberg M, Kopp S, Dressman JB. Classification of orally administered drugs on the World Health Organization model list of essential medicines according to the biopharmaceu-tics classification system. Eur J Pharm Biopharm 2004; 58:265-278.

99. Lennernas H, Abrahamsson B. The use of biopharmaceutic classification of drugs in drug discovery and development: current status and future extension. J Pharm Pharmacol 2005; 57(3):273-285 (review).

100. Baldoni J. Roles of BCS in Drug Development. AAPS Workshop on BE, BCS and Beyond, May 21-23, 2007, North Bethesda, MD, USA.

101. Yazdanian M, Briggs K, Jankovsky C, et al. The "high solubility" definition of the current FDA Guidance on Biopharmaceutical Classification System may be too strict for acidic drugs. Pharm Res 2004; 21(2):293-299.

102. Rinaki E, Dokoumetzidis A, Valsami G, et al. Identification of biowaivers among class II drugs: theoretical justification and practical examples. Pharm Res 2004; 21(9): 1567-1572.

103. World Health Organization, Proposal to waive in vivo bioequivalence requirements for the WHO model list of essential medicines immediate release, solid oral dosage forms, Working document QAS/04.109/Rev.l. Available at: www.who.org. Accessed November 13, 2007.

104. Kortejarvi H, Urtti A, Yliperttula M. Pharmacokinetic simulation of biowaiver criteria: the effects of gastric emptying, dissolution, absorption and elimination rates. Eur J Pharm Sei 2007; 30(2): 155-166.

105. Blume HH, Schug BS. The biopharmaceutics classification system (BCS): class III drugs-better candidates for BA/BE waiver? Eur J Pharm Sei 1999; 9(2): 117-121 (review).

106. Yu LX, Amidon GL, Polli JE, et al. Biopharmaceutics classification system: the scientific basis for biowaiver extensions. Pharm Res 2002; 19(7):921-925.

107. Chen CL, Yu LX, Lee HL, et al. Biowaiver extension potential to BCS class III high solubility-low permeability drugs: bridging evidence for metformin immediate-release table. Eur J Pharm Sei 2004; 22(4):297-304.

108. Vogelpoel H, Welink J, Amidon GL, et al. Biowaiver monographs for immediate release solid oral dosage forms based on biopharmaceutics classification system (BCS) literature data: verapamil hydrochloride, propranolol hydrochloride, and atenolol. J Pharm Sei 2004; 93(8): 1945-1956.

109. Jantratid E, Prakongpan S, Dressman JB, et al. Biowaiver monographs for immediate release solid oral dosage forms: Cimetidine. J Pharm Sei 2006; 95(5):974-984.

110. Kortejärvi H, Yliperttula M, Dressman JB, et al. Biowaiver monographs for immediate release solid oral dosage forms: ranitidine hydrochloride. J Pharm Sei 2005; 94(8): 1617-1625.

111. Koch KM, Parr AF, Tomlinson JJ, et al. Effect of sodium acid pyrophosphate on ranitidine bioavailability and gastrointestinal transit time. Pharm Res 1993; 10(7): 1027-1030.

112. Adkin DA, Davis SS, Sparrow RA, et al. The effect of mannitol on the oral bioavailability of Cimetidine. J Pharm Sei 1995; 84(12): 1405-1409.

113. Custodio JM, Wu C-Y, Benet LZ. Predicting drug disposition, absorption/elimination/ transporter interplay and the role of food on drug absorption. Adv Drug Del Reviews 2008; 60:717-733.

0 0

Post a comment